GlassScriptPhysician profile
Rafael Burgos
NPI 1346203742
$1,682.57
in general payments reported to CMS, 2019-2025
18 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.03 · 2020: $38.93 · 2021: $215 · 2022: $208 · 2023: $485 · 2024: $527 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $261.30 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $245.08 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $170.60 | 2020-2024 | Livalo |
| Idorsia Pharmaceuticals US INC | $151.69 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $131.59 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $113.35 | 2025 | Cobenfy |
| Lilly USA, LLC | $92.96 | 2023-2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $91.74 | 2022-2024 | Veozah |
| Novo Nordisk INC | $85.25 | 2023-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $77.37 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $70.29 | 2022-2024 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $49.82 | 2022 | |
| Glaxosmithkline, LLC. | $47.42 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $21.91 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.36 | 2024 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $19.43 | 2024 | |
| Phadia US INC. | $17.08 | 2021 | |
| Amarin Pharma, INC. | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Burgos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.